This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q79111786
rdf:type
wikibase:Item
schema:description
klinisch onderzoek ensayu clínicu clinical trial клінічне випробування
rdfs:label
Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
skos:prefLabel
Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
schema:name
Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
p:P1476
wds:Q79111786-347A1B3C-8AD7-411A-8517-5FF1D58CBBB8
wdt:P1476
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 in Subjects With Locally Advanced or Metastatic Solid Tumors
p:P582
wds:Q79111786-AC33F162-DA72-4CDD-9ABF-B338C61FA504
wdt:P582
2022-12-02T00:00:00Z
p:P31
wds:Q79111786-E1585CEB-8C3D-4075-A1AF-DD47D7DC6FAD
wdt:P31
wd:Q30612
p:P580
wds:Q79111786-B1998ED8-15D4-48B0-B940-E8C26556CBF8
wdt:P580
2019-12-10T00:00:00Z
p:P17
wds:Q79111786-C2903B5A-2A91-4D5F-A735-D9F4B674BA0B
wdt:P17
wd:Q30
p:P921
wds:Q79111786-3EA6F181-61C4-4FA8-9743-4A29304628BA
wdt:P921
wd:Q18975694
p:P4844
wds:Q79111786-13C4784C-904F-4A74-836E-5A94C248522C
wdt:P4844
wd:Q13896859
p:P2899
wds:Q79111786-455D61E8-D13F-4EBC-8703-71F6A3C311CC
wdt:P2899
18
p:P1050
wds:Q79111786-45B1AE4A-5EA8-4329-B167-2EA9557CC705 wds:Q79111786-88C2D4A0-8543-4265-8D9E-6BCDD10C5F90
wdt:P1050
wd:Q33525 wd:Q180614
p:P1132
wds:Q79111786-0AFE11F7-E83D-4A27-A040-163B7F12B219
wdt:P1132
150
p:P8363
wds:Q79111786-B385B732-7342-42BC-BDF2-737EC3AD221E
wdt:P8363
wd:Q78089383
p:P3098
wds:Q79111786-A447C0E4-79FA-45D7-B32F-C225F3BA6F7C
wdt:P3098
NCT04198766
p:P6099
wds:Q79111786-AC54A07C-78ED-479A-9C74-AA6F582AD98C
wdt:P6099
wd:Q5452194